neuropathic pain market and - pharma intelligence/media/in... · pharma intelligence | informa...

YEAR US JAPAN FRANCE GERMANY ITALY SPAIN UKGRANDTOTAL

2017201820192020202120222023202420252026

7,6198,0245,7385,5665,6395,7855,9655,9806,1396,133

404395388382375364350339329319

45434241404040404041

199185182178176174174175179188

70696969707071727372

52535455555556575958

130132134136138140142144147152

8,5198,9016,6076,4276,4926,6286,7976,8076,9656,962

Datamonitor Healthcare Pharma intelligence | informa

Report Store Pharma intelligence | informa

Datamonitor Healthcare estimates the neuropathic pain market to total $8.5bn in 2017 across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK).

Neuropathic pain sales will decline at a CAGR of -2.2% over 2017–26, peaking at $8.9bn in 2018 before contracting due to Lyrica’s patent cliff.

The primary driver of initial market growth relies on continued uptake of gold-standard Lyrica, as effective alternatives remain few and far between.

Neuropathic Pain Market and Forecast Analysis to 2026

Neuropathic pain drug sales acrossthe US, Japan, and five major EUmarkets, by country ($m), 2017-26

NOTICE: TOTALS MAY NOT SUM

DUE TO ROUNDING

ANTI-CONVULSANTS

ANTI-DEPRESSANTS ANXIOLYTICS

GENE THERAPIES OPOIDS

OTHER ORALGESTICS

GRANDTOTAL

2017201820192020202120222023202420252026

729713741750758766775784794803

4,4534,7002,2931,9881,8961,8371,7931,5821,5241,552

344346352357363370377385393401

2222222222

---338101176263363458

2,8492,9723,0633,1643,2663,3763,4913,6013,6933,543

142149156163169176183190197204

8,5198,9016,6076,4276,4926,6286,7976,8076,9656,962

ANESTHETICSYEAR

Drug sales across the US, Japan, and five major EU markets, by DRUG CLASS ($m), 2017-26

CompanyNovartis

Aeterna

GET THE FULL REPORT

HERE

CLICK HERE

“With Lyrica’s patent cliff, Datamonitor Healthcare estimates that neuropathic pain sales will fall from $8.52bn in 2017 to $6.96bn in 2026” CLICK TO TWEET THIS!

The full 290-page report includes an assessment of:

• Key neuropathic pain therapies on the market and in the late-phase pipeline

• Neuropathic pain market dynamics

• A 10-year patient-based sales forecast.

20% discount

pain20

use the code below to get your discount